亨廷頓舞蹈症治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Huntingtons Disease Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月08日 | 出版商:

Global Market Insights Inc. | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年全球亨廷頓舞蹈症治療市值為4.575億美元，預計2024-2032年複合年成長率為20.8%。這種成長是由亨廷頓舞蹈症的日益流行和醫學研究的重大進步所推動的。診斷工具的改進和意識的提高導致了更多病例的發現，從而推動了對有效治療的需求。基因檢測的進步現在可以實現更早、更準確的診斷，從而促進及時介入。關鍵藥物（例如丁苯那嗪）的學名藥的出現，使得治療變得更加經濟實惠和容易獲得。此外，政府、製藥公司和私人投資者增加的資金和投資正在加速新療法的發現和開發，進一步促進市場擴張。

整個亨廷頓舞蹈症治療產業根據藥物、類型、配銷通路和地區進行分類。

市面上將藥物分為丁苯那嗪、丁苯那嗪和其他藥物。 2023年，丁苯那嗪佔據主導地位，佔據47.8%的市場。丁苯那嗪可有效治療舞蹈症（亨丁頓舞蹈症的主要症狀）、減少不自主運動並改善運動功能。它作為亨廷頓氏舞蹈症的特定治療方法的早期監管批准和認可鞏固了其市場地位。品牌和學名藥形式的可用性提供了具有成本效益的治療選擇，保持了其重要的市場佔有率。

市場細分為品牌和通用類別。 2023 年，在既定功效和強大品牌認知度的推動下，品牌細分市場銷售額達 2.58 億美元。品牌藥物受益於全面的監管批准和臨床指南的頻繁認可，鞏固了其作為各種病症標準治療的地位。廣泛的行銷活動和持續的研發投資進一步增強了品牌治療的吸引力，確保它們始終處於醫療實踐的前沿。

2023年，北美亨廷頓舞蹈症治療市值為1.839億美元，預計複合年成長率為20.7%。北美亨廷頓舞蹈症的盛行率很高，人們的認知和早期診斷能力也有所提高。改進的診斷工具和宣傳活動導致了更高的診斷率和對有效治療的更大需求。 2023 年，美國亨廷頓舞蹈症治療市場價值為 1.677 億美元，預計到 2032 年將達到 8.944 億美元。

產業生態系統分析
產業影響力
- 成長動力
  - 亨丁頓舞蹈症的盛行率不斷增加
  - 增加與亨丁頓舞蹈症相關的研發活動
  - 人們對這種疾病的認知不斷增強
- 產業陷阱與挑戰
  - 有效治療的可用性有限
  - 嚴格的監管要求
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按藥品分類，2021 - 2032 年

主要趨勢
丁苯那嗪
丁苯那嗪
其他藥品

第 6 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
品牌化
通用的

第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Bausch Health Companies Inc.
CHEPLAPHARM Arzneimittel GmbH
Dr. Reddy's Laboratories Ltd.
H. Lundbeck A/S
Hikma Pharmaceuticals PLC
Lupin Limited
Neurocrine Biosciences, Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Upsher-Smith Laboratories, LLC.

簡介目錄

Product Code: 10732

The Global Huntington's Disease Treatments Market was valued at USD 457.5 million in 2023, with a projected CAGR of 20.8% over 2024-2032. This growth is fueled by the increasing prevalence of Huntington's disease and significant advancements in medical research. Improved diagnostic tools and greater awareness have led to the identification of more cases, driving the demand for effective treatments. Advances in genetic testing now enable earlier and more accurate diagnoses, facilitating timely interventions. The availability of generic versions of key medications, such as tetrabenazine, has made treatments more affordable and accessible. Additionally, increased funding and investment from governments, pharmaceutical companies, and private investors, are accelerating the discovery and development of new therapies, further contributing to market expansion.

The overall huntingtons disease treatment industry is classified based on the drugs, type, distribution channel, and region.

The market categorizes drugs into tetrabenazine, deutetrabenazine, and other medications. In 2023, tetrabenazine dominated with a 47.8% market share. Tetrabenazine is effective for managing chorea, a major symptom of Huntington's disease, reducing involuntary movements, and improving motor function. Its early regulatory approval and recognition as a specific treatment for Huntington's disease solidifies its market position. Availability in both branded and generic forms provides cost-effective treatment options, maintaining its significant market share.

The market segments treatments into branded and generic categories. In 2023, the branded segment accounted for USD 258 million, driven by established efficacy and strong brand recognition. Branded medications benefit from comprehensive regulatory approval and frequent endorsements in clinical guidelines, reinforcing their position as standard treatments for various conditions. Extensive marketing campaigns and continued investment in research and development further strengthen the appeal of branded treatments, ensuring they remain at the forefront of medical practice.

In 2023, the North American market for Huntington's disease treatments was valued at USD 183.9 million, with a projected CAGR of 20.7%. North America has a high prevalence of Huntington's disease, coupled with increased awareness and early diagnostic capabilities. Improved diagnostic tools and awareness campaigns have led to higher diagnosis rates and greater demand for effective treatments. In 2023, the U.S. market for Huntington's disease treatments was valued at USD 167.7 million, projected to reach USD 894.4 million by 2032. The U.S. is a hub for pharmaceutical R&D, with significant investments in developing new therapies for Huntington's disease, supporting growth in the region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of Huntington's disease
  - 3.2.1.2 Increased research and development activities related to Huntington's disease
  - 3.2.1.3 Growing awareness related to the disease
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Limited availability of effective treatment
  - 3.2.2.2 Stringent regulatory requirement
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drugs, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Tetrabenazine
5.3 Deutetrabenazine
5.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Branded
6.3 Generic

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa